Search

Your search keyword '"Perrin, Lewis C."' showing total 33 results
Start Over Author "Perrin, Lewis C."
33 results on '"Perrin, Lewis C."'

1. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial

Author

Janda, Monika, Robledo, Kristy P., Gebski, Val, Armes, Jane E., Alizart, Michelle, Cummings, Margaret, Chen, Chen, Leung, Yee, Sykes, Peter, McNally, Orla, Oehler, Martin K., Walker, Graeme, Garrett, Andrea, Tang, Amy, Land, Russell, Nicklin, James L., Chetty, Naven, Perrin, Lewis C., Hoet, Greet, Sowden, Katherine, Eva, Lois, Tristram, Amanda, and Obermair, Andreas

Published
2021
Full Text
View/download PDF

2. Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high‐grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context

Author

Samoylovich, Arthur, primary, Jennings, Bronwyn, additional, Shannon, Catherine, additional, Coward, Jermaine I., additional, Lourie, Rohan, additional, Riordan, John, additional, Lai, Nai An, additional, van Driel, Willemien J., additional, Cabraal, Nimithri, additional, Jagasia, Nisha, additional, Chetty, Naven, additional, Naidu, Sanjeev, additional, Perrin, Lewis C., additional, and Barry, Sinead C., additional

Published
2023
Full Text
View/download PDF

7. Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer

Author

He, Yaowu, primary, Khan, Tashbib, additional, Kryza, Thomas, additional, Jones, Martina L., additional, Goh, Justin B., additional, Lyons, Nicholas J., additional, Pearce, Lesley A., additional, Lee, Michael D, additional, Gough, Madeline, additional, Rogers, Rebecca, additional, Davies, Claire M, additional, Gilks, C. Blake, additional, Hodgkinson, Thomas, additional, Lourie, Rohan, additional, Barry, Sinead C., additional, Perrin, Lewis C., additional, Williams, Charlotte C., additional, Puttick, Simon, additional, Adams, Timothy E., additional, Munro, Trent P., additional, Hooper, John D., additional, and Chetty, Naven, additional

Published
2021
Full Text
View/download PDF

11. Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma

Author

Khan, Tashbib, primary, He, Yaowu, additional, Kryza, Thomas, additional, Harrington, Brittney S., additional, Gunter, Jennifer H., additional, Sullivan, Mitchell A., additional, Cuda, Tahleesa, additional, Rogers, Rebecca, additional, Davies, Claire M., additional, Broomfield, Amy, additional, Gough, Madeline, additional, Wu, Andy C., additional, McGann, Thomas, additional, Weroha, S. John, additional, Haluska, Paul, additional, Forbes, Josephine M., additional, Armes, Jane E., additional, Barry, Sinead C., additional, Coward, Jermaine I., additional, Jagasia, Nisha, additional, Chetty, Naven, additional, Snell, Cameron E., additional, Lourie, Rohan, additional, Perrin, Lewis C., additional, and Hooper, John D., additional

Published
2020
Full Text
View/download PDF

12. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

Author

Harrington, Brittney S., primary, He, Yaowu, additional, Khan, Tashbib, additional, Puttick, Simon, additional, Conroy, Paul J., additional, Kryza, Thomas, additional, Cuda, Tahleesa, additional, Sokolowski, Kamil A, additional, Tse, Brian WC, additional, Robbins, Katherine K., additional, Arachchige, Buddhika J., additional, Stehbens, Samantha J., additional, Pollock, Pamela M., additional, Reed, Sarah, additional, Weroha, S. John, additional, Haluska, Paul, additional, Salomon, Carlos, additional, Lourie, Rohan, additional, Perrin, Lewis C., additional, Law, Ruby H. P., additional, Whisstock, James C., additional, and Hooper, John D, additional

Published
2020
Full Text
View/download PDF

20. Corrigendum to “Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial” [Gynecologic Oncology 161 (2021) 143–151]

Author

Janda, Monika, Robledo, Kristy P., Gebski, Val, Armes, Jane E., Alizart, Michelle, Brennan, Donal, Cummings, Margaret, Chen, Chen, Leung, Yee, Sykes, Peter, McNally, Orla, Oehler, Martin K., GraemeWalker, Garrett, Andrea, Tang, Amy, Land, Russell, Nicklin, James L., Chetty, Naven, Perrin, Lewis C., Hoet, Greet, Sowden, Katherine, Eva, Lois, Tristram, Amanda, and Obermair, Andreas

Published
2021
Full Text
View/download PDF

22. L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution

Author

Nguyen, Thu H.M., primary, Carreira, Patricia E., additional, Sanchez-Luque, Francisco J., additional, Schauer, Stephanie N., additional, Fagg, Allister C., additional, Richardson, Sandra R., additional, Davies, Claire M., additional, Jesuadian, J. Samuel, additional, Kempen, Marie-Jeanne H.C., additional, Troskie, Robin-Lee, additional, James, Cini, additional, Beaven, Elizabeth A., additional, Wallis, Tristan P., additional, Coward, Jermaine I.G., additional, Chetty, Naven P., additional, Crandon, Alexander J., additional, Venter, Deon J., additional, Armes, Jane E., additional, Perrin, Lewis C., additional, Hooper, John D., additional, Ewing, Adam D., additional, Upton, Kyle R., additional, and Faulkner, Geoffrey J., additional

Published
2018
Full Text
View/download PDF

24. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer

Author

Harrington, Brittney S, primary, He, Yaowu, additional, Davies, Claire M, additional, Wallace, Sarah J, additional, Adams, Mark N, additional, Beaven, Elizabeth A, additional, Roche, Deborah K, additional, Kennedy, Catherine, additional, Chetty, Naven P, additional, Crandon, Alexander J, additional, Flatley, Christopher, additional, Oliveira, Niara B, additional, Shannon, Catherine M, additional, deFazio, Anna, additional, Tinker, Anna V, additional, Gilks, C Blake, additional, Gabrielli, Brian, additional, Brennan, Donal J, additional, Coward, Jermaine I, additional, Armes, Jane E, additional, Perrin, Lewis C, additional, and Hooper, John D, additional

Published
2016
Full Text
View/download PDF

30. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix.

Author

Sok Cheon Pak, Martens, Martje, Bekkers, Ruud, Crandon, Alex J., Land, Russell, Nicklin, James L., Perrin, Lewis C., and Oberamir, Andreas

Subjects
PAP test, SQUAMOUS cell carcinoma, HISTOPATHOLOGY, HEMORRHAGE, CERVICAL cancer, CANCER diagnosis
Abstract

Background: Since the introduction of the Pap smear screening, the incidence of squamous cell carcinoma (SCC) has decreased significantly, but the incidence of adenocarcinoma (AC) relative to SCC has increased. Aim: To compare the Pap smear history of patients with AC and SCC of the cervix. Methods: Patients for the study were identified from the database of Queensland Centre for Gynaecological Cancer. Patients with AC and SCC were matched for age at diagnosis and International Federation of Gynecology and Obstetrics stage. The final population included 188 matched pairs, being 376 patients in total. Data were collected upon the histological type of cancer, result of the most recent Pap smear, date and result of the Pap smear prior to the most recent Pap smear and symptoms. Chi-squared tests and Fisher's exact test were used to compare the two patient groups for several variables. Results: Patients with AC had significantly more false-negative results on their most recent Pap smear ( P < 0.0001) than patients with SCC. The incidence of symptoms such as bleeding and/or vaginal discharge was comparable in patients with AC and SCC. The time between the most recent Pap smear and the diagnosis of cervical cancer was significantly shorter for patients with AC ( P = 0.01). Conclusions: Patients with AC had Pap smears more regularly than those with SCC, and their most recent Pap smear was significantly more likely to be normal. Thus, Pap smear prior to a diagnosis of AC is more likely than SCC false-negative and therefore not indicative of cervical cancer. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

31. Safety and Efficacy of Low Anterior en BlocResection as Part of Cytoreductive Surgery for Patients with Ovarian Cancer

Author

Obermair, Andreas, Hagenauer, Sabine, Tamandl, Dietmar, Clayton, Rick D., Nicklin, James L., Perrin, Lewis C., Ward, Bruce G., and Crandon, Alex J.

Abstract

Objective.To examine the feasibility and safety of a low anterior resection of the rectosigmoid plus adjacent pelvic tumour as part of primary cytoreduction for ovarian cancer.

Published
2001
Full Text
View/download PDF

32. Efficacy of routine follow-up in patients with recurrent uterine cancer

Author

Smith, Christopher J., Heeren, Monique, Nicklin, James L., Perrin, Lewis C., Land, Russell, Crandon, Alex J., and Obermair, Andreas

Subjects
*CANCER patients, *ONCOLOGY, *TUMORS, *CYTOLOGY
Abstract

Abstract: Objective. : To evaluate the efficacy of routine follow-up in patients with recurrent uterine cancer. Methods. : In a single institution study, a total of 2637 patients were treated curatively for uterine cancer from 1990 to 2006. A total of 438 patients experienced disease recurrence. Data for detailed analysis were available from 280 of the 438 patients. Prior to the diagnosis of recurrence, all patients had regular follow-up and were investigated through internal examination, vaginal vault cytology and imaging. Overall survival (OS) was the main study endpoint and was calculated from recurrence diagnosis to death or date censored. Results. : Clinical and histopathological features as well as patterns of recurrence were similar in symptomatic and asymptomatic patients. Eighty-one patients (28.9%) were diagnosed with asymptomatic recurrence while 199 patients (71.1%) presented with symptomatic recurrence. The overall survival probability at 5 years was 41.0% and 28.9% respectively for asymptomatic and symptomatic patients (log-rank p =0.013). Those patients with stage 1 or 2 tumors of endometrioid type were found to have an overall survival probability at 5 years of 38.0% and 25.7% respectively for asymptomatic and symptomatic recurrence (log-rank p =0.05). The absence of symptoms did not impact on the outcome of patients with stage 3 tumors or tumors of non-endometrioid type. Conclusions. : While patients at low/intermediate risk of recurrence may benefit from intensive follow-up including internal examinations, routine vaginal vault cytology and imaging, high-risk patients might gain more from an alternate follow-up strategy with emphasis on imaging in conjunction with symptom education. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

33. Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer.

Author

Dutt M, Hartel G, Richards RS, Shah AK, Mohamed A, Apostolidou S, Gentry-Maharaj A, Hooper JD, Perrin LC, Menon U, and Hill MM

Subjects
Humans, Female, Biomarkers, Tumor metabolism, Tandem Mass Spectrometry methods, Glycoproteins, Lectins, Aryldialkylphosphatase, Ovarian Neoplasms diagnosis, Cystadenocarcinoma, Serous
Abstract

Purpose: This study aimed to identify serum glycoprotein biomarkers for early detection of high-grade serous ovarian cancer (HGSOC), the most common and aggressive histotype of ovarian cancer., Experimental Design: The glycoproteomics pipeline lectin magnetic bead array (LeMBA)-mass spectrometry (MS) was used in age-matched case-control serum samples. Clinical samples collected at diagnosis were divided into discovery (n = 30) and validation (n = 98) sets. We also analysed a set of preclinical sera (n = 30) collected prior to HGSOC diagnosis in the UK Collaborative Trial of Ovarian Cancer Screening., Results: A 7-lectin LeMBA-MS/MS discovery screen shortlisted 59 candidate proteins and three lectins. Validation analysis using 3-lectin LeMBA-multiple reaction monitoring (MRM) confirmed elevated A1AT, AACT, CO9, HPT and ITIH3 and reduced A2MG, ALS, IBP3 and PON1 glycoforms in HGSOC. The best performing multimarker signature had 87.7% area under the receiver operating curve, 90.7% specificity and 70.4% sensitivity for distinguishing HGSOC from benign and healthy groups. In the preclinical set, CO9, ITIH3 and A2MG glycoforms were altered in samples collected 11.1 ± 5.1 months prior to HGSOC diagnosis, suggesting potential for early detection., Conclusions and Clinical Relevance: Our findings provide evidence of candidate early HGSOC serum glycoprotein biomarkers, laying the foundation for further study in larger cohorts., (© 2023 The Authors. Proteomics - Clinical Applications published by Wiley-VCH GmbH.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results